New drug combo aims to tackle Hard-to-Treat myeloma
NCT ID NCT05927571
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor side effects and determine the best dose for future studies. The goal is to find a new option for this difficult-to-treat blood cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cevostamab and elranatamab (two cancer drugs given by infusion or injection)
What this could lead to
If this combination works, it could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial, so the main goal is safety, not proof of effectiveness. The drugs may cause side effects like cytokine release syndrome, and the combination might not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center.
RECRUITINGSeoul, 05505, South Korea
-
Calvary Mater Newcastle
RECRUITINGWaratah, New South Wales, 2298, Australia
-
Hadassah University Hospital - Ein Kerem
RECRUITINGJerusalem, 9112001, Israel
-
Rambam Health Care Campus
RECRUITINGHaifa, 3109600, Israel
-
Royal Adelaide Hospital;Haematology Clinical Trials Unit
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Royal Prince Alfred Hospital
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Samsung Medical Center - PPDS
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
St. Vincent's Hospital Melbourne
RECRUITINGMelbourne, Victoria, 3065, Australia
-
Tel Aviv Sourasky Medical Center PPDS
RECRUITINGTel Aviv, 6423906, Israel
-
The Alfred Hospital
RECRUITINGPrahan, Victoria, 3181, Australia
-
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital)
RECRUITINGSeocho, 06591, South Korea
-
The Chaim Sheba Medical Center - PPDS
RECRUITINGRamat Gan, Central District, 5262100, Israel